Glucocorticoids decrease cytochrome c oxidase activity of isolated rat kidney mitochondria  by Simon, Nicolas et al.
Glucocorticoids decrease cytochrome c oxidase activity of isolated rat
kidney mitochondria
Nicolas Simon, Pascale Jolliet, Christophe Morin, Roland Zini, Sa|ºk Urien*,
Jean-Paul Tillement
DeŁpartment de Pharmacologie, FaculteŁ de MeŁdecine de Paris XII, 8 rue du GeŁneŁral Sarrail, F-94010 CreŁteil, France
Received 15 June 1998; revised version received 10 August 1998
Abstract The importance of mitochondria is rising as a target
in pathologic processes such as ischemia. We have investigated
the effects of hydrocortisone, prednisolone, dexamethasone and
triamcinolone on oxidative phosphorylation, Ca2+ fluxes, swel-
ling and membrane potentials in isolated kidney mitochondria.
The measurement of respiration state 3 showed a significant
decrease in presence of glucocorticoids whereas the other
respiration states were not modified. When mitochondria were
uncoupled and either the complexes III and IV or the complex IV
were stimulated, the O2 consumption was decreased by
glucocorticoids. These results suggest the cytochrome c oxidase
is a target of the glucocorticoid effect on the respiratory chain.
Indeed, the other mitochondrial functions investigated were
unchanged, ruling out a direct effect on Ca2+ fluxes or swelling.
A regulation of cytochrome c oxidase activity by glucocorticoids
will be of particular interest in pathology involving metabolic
insult.
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1. Introduction
Glucocorticoids are potent immunosuppressive agents ex-
tensively used after organ transplantation [1]. Their relevant
pharmacological properties are still not completely known.
They inhibit the synthesis of almost all known cytokines
and several cell surface molecules required for immune func-
tion. Recently, the nuclear factor kappa B (NF-KB) which
activates many immunoregulatory genes was suggested to be
a target for glucocorticoid-mediated immunosuppression [2,3].
Furthermore, dexamethasone is a well-known inducer of thy-
mocyte apoptosis [4]. The exact mechanism of this e¡ect is not
well de¢ned but involves alterations of mitochondrial struc-
tures and functions which suggest that these organelles are
involved in the process [4]. Other mitochondrial e¡ects have
been suggested for glucocorticoids. Djouadi et al. [5] have
shown a cell-speci¢c regulation of rat kidney oxidative metab-
olism by glucocorticoids. The mechanism could be a direct
e¡ect on mitochondrial gene transcription [6]. Thus glucocor-
ticoids could be involved in mitochondria biogenesis and in
the development of respiratory chain enzymes [7]. However,
the authors suggest that these activities do not regulate post-
natal changes in mitochondrial density and mitochondrial
DNA content.
The e¡ects of steroid treatment on energy metabolism have
already been described [8] but nothing is known on the com-
parative e¡ects of glucocorticoids on oxidative phosphoryla-
tion, Ca2 £uxes, membrane potentials and swelling. So, we
investigated the mitochondrial e¡ects of hydrocortisone, pred-
nisolone, triamcinolone and dexamethasone in vitro using rat
kidney mitochondria.
2. Materials and methods
2.1. Materials
Sucrose, EGTA, D-mannitol, rotenone, malonate, antimycin A, oli-
gomycin, succinate, malate, pyruvate, ADP, carbonyl cyanide m-
chlorophenylhydrazone (CCCP), sodium ascorbate, N,N,NP,NP-tetra-
methyl-p-phenylenediamine (TMPD), decylubiquinone (DUQ), and
bovine serum albumin (BSA) were purchased from Sigma (Saint
Quentin Fallavier, France). KCl and MgCl2 were obtained from Pro-
labo (Paris, France). KH2PO4 was purchased from Merck (Paris,
France).
Hydrocortisone, prednisolone, triamcinolone and dexamethasone
were purchased from Sigma Chemical Company. They were solubi-
lized in dimethylformamide (DMF) and distilled water (v:v) in order
to obtain a stock solution at 1033 M. All the controls were carried out
using the same solvent mixture. The ¢nal solution contained no more
than 0.05% DMF.
Decylubiquinol (DUQH2) was immediately prepared from decyl-
ubiquinone (DUQ) as described by Veitch et al. [9]. The solution
was evaporated to dryness under nitrogen gas, dissolved in 1 ml of
DMF and stored at 370‡C until used.
2.2. Methods
2.2.1. Isolation of kidney mitochondria. Mitochondria were ex-
tracted from a homogenate of one rat kidney by di¡erential centrifu-
gations according to Simon et al. [10]. Rats (male, Wistar, weighing
280^300 g) were killed by decapitation and the kidneys removed and
placed quickly in an ice-bath. The kidneys were then minced in ice-
cold isolation medium (Tris 20 mM, sucrose 250 mM, KCl 40 mM,
EGTA 2 mM and bovine serum albumin 1 mg/ml; pH 7.2) and
homogenized (6 ml/g of tissue) using a Potter-Elvejhem homogenizer.
Mitochondria isolation was performed at 4‡C without delay using
di¡erential centrifugation: the homogenate was centrifuged at
2000Ug for 8 min to remove cell debris and nuclei, mitochondria
were separated from the supernatant by centrifugation at 12 000Ug
for 10 min. The pellet (mitochondria) was washed and resuspended in
a medium containing sucrose 250 mM, KH2PO4 5 mM for the Ca2
£uxes, membrane potentials and induced swelling experiments, or in a
respiratory bu¡er (mannitol 300 mM, KH2PO4 10 mM, KCl 10 mM,
MgCl2 5 mM, pH 7.2) for measuring respiratory activity. Protein
concentrations of the mitochondrial suspension were determined by
the method of Lowry. All assays were done on freshly isolated mito-
chondria. This protocol meets the guidelines of the french agency
regarding animal experimentation (authorization No. 00748 delivered
to Prof. J.P. Tillement).
2.2.2. Assay of mitochondrial oxygen consumption. Oxygen uptake
was determined with a Clark-type microelectrode (Hansatech, UK).
Each experiment was carried out as follows: 45 Wl of mitochondria
suspension were preincubated during 10 min at 4‡C with (or without)
the tested drug, then incubated 1 min at 37‡C in 500 Wl of the respi-
ratory bu¡er (400 to 1200 Wg/ml proteins) without or with the inhib-
itors, then the substrate was added and oxygen consumption was
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checked (state 2). To initiate state 3 respiratory activity, 200 WM ADP
was added to the cuvette. When all ADP was converted to ATP
the state 4 was measured. The following parameters were determined:
the respiratory rates calculated as nanomoles of O2 per min per mg
of mitochondrial protein, the respiratory control ratio (RCR) ex-
pressed as the ratio of state 3/state 4 oxygen consumption and the
P/O ratio.
The rate of oxygen consumption by the di¡erent complexes was
determined according to Rustin et al. [11]. Brie£y, rotenone (2 WM),
malonate (10 mM), antimycin (1 WM), and oligomycin (10 WM) were
used to inhibit complexes I, II, III and V, respectively and carbon-
ylcyanure-m-chlorophenylhydrazone (CCCP) was added as decou-
pling agent (10 WM). Malate (10 mM) plus pyruvate (10 mM), succi-
nate (10 mM), decylubiquinone (150 WM), ascorbate (5 mM) plus
TMPD (1 mM) were used as substrates for complexes I, II, III and
IV respectively.
2.2.3. Ca2+ £uxes. A speci¢c Ca2 electrode (Orion 9320) ¢tted to
a Hansatech recorder via a 720A Orion ionometer was used to record
Ca2 movements in extramitochondrial medium in a thermostat-con-
trolled reaction chamber (3.8 ml) at 37‡C containing sucrose 250 mM,
KH2PO4 5 mM, plus succinate 6 mM. The study was performed in
presence of 25 WM of Ca2. Glucocorticoid e¡ects were measured at
1 WM and were added prior to Ca2 and mitochondria to ensure that
they did not modify the electrode response. The Ca2 concentration in
extramitochondrial medium decreased rapidly when mitochondria
(2 mg/ml of protein) were added, due to Ca2 uptake into mitochon-
dria. After all of the oxygen in the medium was consumed, anaero-
biosis lead to Ca2 release.
2.2.4. Measurement of swelling of energized mitochondria. Mito-
chondria (2 mg/ml of protein) were added to 1.8 ml of a medium
containing sucrose 250 mM, KH2PO4 5 mM and rotenone 3 WM at
37‡C. After mixing, swelling was initiated by addition of Ca2 25 WM
plus succinate 6 mM to the sample cuvette. Swelling of energized
mitochondria was determined by measuring the decrease of optical
density at 520 nm, with a Hitachi spectrophotometer (U3000).
2.2.5. Measurement of membrane potentials. Absorbance measure-
ments were made at high concentrations of rhodamine 123 (0.3 WM)
with a Perkin Elmer luminescence spectrometer using 0.1 mm cuv-
ettes. For each measure 1 ml of a medium containing sucrose (250
mM), KH2PO4 (5 mM), succinate (6 mM), rotenone (3 WM) and the
drugs tested (1 WM) were added in the cuvette at 37‡C. When the
£uorescence was stabilized (10 s), mitochondria (0.5 mg/ml of protein)
were added to the sample cuvette. Then, the £uorescence decreased
according to rhodamine in£ux into mitochondria. We also investi-
gated the e¡ect of glucocorticoid on membrane potential in presence
of high concentration of Ca2 (50 WM).
The mitochondria membrane potential was calculated by the Nernst
equation (Equation 1) according to Emaus et al. [12] and expressed in
mV.
v8m  61:41Ulogrhodaminein=rhodamineout: 1
2.2.6. Statistical analysis. For each experiment, mean values of
RCR or percentages were compared with a one-way analysis of var-
iance. EC50 was calculated by non-linear regression ¢t of e¡ect-con-
centration curve to the equation:
E  EmaxUC=C  EC50;
where Emax and EC50 are the maximal e¡ect and the concentration
producing 50% e¡ect respectively, using a commercially available soft-
ware (Micropharm) [13].
3. Results
3.1. Oxygen consumption
When the respiratory chain was activated by malate/pyru-
vate and ADP (complexes I to V), the RCR was signi¢cantly
decreased from 12 to 21% for all the glucocorticoids (Table 1).
Signi¢cant inhibition of state 3 was observed whereas the state
4 was not modi¢ed. So the decrease of RCR value was due to
a decrease of state 3 except for hydrocortisone where a slight
increase of state 4 occurred. The P/O ratio remained similar to
the control.
When the respiratory chain was activated by succinate and
complex I inhibited by rotenone, glucocorticoids decreased
signi¢cantly RCR (Fig. 1). This e¡ect was concentration-de-
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Table 1
Glucocorticoid e¡ects on oxydative respiration of isolated rat kidney mitochondria
State 2 State 3 State 4 RCR P/O Complex III and Complex IV
(nmol O2
min31 mg31)
(nmol O2
min31 mg31)
(nmol O2
min31 mg31)
IV (nmol O2
min31 mg31)
(nmol O2
min31 mg31)
Control 6.74 (1.28) 46.65 (8.34) 7.13 (0.92) 6.54 (0.86) 2.27 (1.07) 76.59 (24.19) 348.61 (22.81)
Hydrocortisone 7.72 (1.06) 41.85 (8.91) 7.26 (1.39) 5.76 (0.33)* 2.23 (0.85) 50.52 (16.53)* 271.37 (72.24)*
Prednisolone 6.70 (1.43) 37.30 (8.11)* 7.07 (1.37) 5.27 (0.90)** 2.17 (0.68) 50.67 (13.25)* 262.67 (74.39)*
Triamcinolone 7.22 (1.34) 35.26 (7.41)** 6.34 (1.12) 5.56 (0.72)* 2.28 (0.69) 49.90 (17.41)* 263.63 (70.78)*
Dexamethasone 6.44 (0.99) 32.99 (6.04)** 6.40 (0.80) 5.15 (0.80)** 2.38 (0.56) 49.25 (18.49)* 264.57 (75.98)*
*P6 0.05 and **P6 0.01. Each value represents the mean ( þ S.D.) of six determinations. The duration time for glucocorticoid incubation (1 WM)
was 15 min. The controls were carried out using an equivalent volume of dimethylformamide (0.05%). At the beginning to activate complexes I to
V, the oxygen consumption was measured with malate (10 mM) plus pyruvate (10 mM) as substrates and ADP (0.2 mM) for a mitochondrial
concentration of 1.2 mg/ml. To investigate complexes III and IV, the oxygen consumption was measured with rotenone (2 WM), malonate (10 mM)
and oligomycine (10 WM) in order to inhibit complexes I, II and V, and decylubiquinone (150 WM) plus carbonyl cyanide m-chlorophenylhydrazone
(CCCP, 150 WM). Then complex III was inhibited by antimycin (1 WM) and complex IV was stimulated by sodium ascorbate (5 mM) and
N,N,NP,NP-tetramethyl-p-phenylenediamine (TMPD, 1 mM). The mitochondrial concentration for these last experiments was 0.4 mg/ml.
Fig. 1. E¡ect of hydrocortisone, prednisolone, triamcinolone and
dexamethasone on respiratory control ratio (RCR) of rat kidney mi-
tochondria. Concentration-response curves were expressed as the
percentages of RCR, hydrocortisone (closed circles), prednisolone
(open circles), triamcinolone (closed squares) and dexamethasone
(open squares). All experiments were carried out at 37‡C with succi-
nate and rotenone, without EGTA in the respiratory bu¡er. Each
point is the mean þ S.D. of eight determinations.
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pendent leading to a biphasic curve with two EC50 values for
prednisolone and dexamethasone. The EC50 values were
9.22U10312 M and 1.94U1038 M for prednisolone;
2.13U10311 M and 8.24U1039 M for dexamethasone;
8.48U10310 M for triamcinolone and 1.14U1037 M for hy-
drocortisone. The maximal inhibitory e¡ect varied from
14.31% to 28.85% with dexamethasone (14.31%)6 hydrocor-
tisone (16.25%)6 triamcinolone (24.66%)6 prednisolone
(28.85%). These results show that glucocorticoids decrease
oxidative phosphorylation without inhibiting complex I. Since
EGTA did not modify the glucocorticoid e¡ects, they could
be considered Ca2-independent (data not shown).
When complexes III and IV were activated alone, glucocor-
ticoids (1 WM) reduced signi¢cantly oxygen consumption with
a similar 35% extent (Table 1). Finally, when complex IV
operated alone, glucocorticoids (1 WM) still modi¢ed oxygen
consumption (Table 1). The complex IV inhibition was similar
between the glucocorticoids (22 to 25%).
3.2. Ca2+ £uxes through mitochondria
Ca2 overloading experiments were carried out to con¢rm
the Ca2 dependency of the mitochondrial e¡ects of glucocor-
ticoids. None of the glucocorticoids (1 WM) tested modi¢ed
Ca2 £uxes (Fig. 2).
3.3. Swelling of energized mitochondria
Glucocorticoids (1 WM) did not modify the swelling of ener-
gized mitochondria induced by 25 WM Ca2 plus inorganic
phosphate (KH2PO4 5 mM). The rates of swelling were
112%, 106%, 113%, 119% versus control for hydrocortisone,
prednisolone, triamcinolone and dexamethasone respectively.
3.4. Membrane potential of mitochondria
Glucocorticoid e¡ects on membrane potential were investi-
gated with or without high concentration of Ca2 (50 WM).
Without Ca2 none of the glucocorticoids tested had a sig-
ni¢cant e¡ect on membrane potential. However with 50 WM
Ca2, they decreased the membrane potential and this de-
crease was signi¢cant for prednisolone and dexamethasone
(Table 2).
4. Discussion
The e¡ects of steroids on mitochondria and energy metab-
olism have already been investigated. Kerppola has previously
described a decrease in state 3 oxygen consumption in rats
treated during 7 days with cortisone acetate [14]. At the op-
posite, Wakat and Haynes have shown after a short-term
administration of glucocorticoids to rats (3 h before experi-
ment) an increase of substrate utilization by isolated hepatic
mitochondria [8]. These e¡ects were produced by cortisol,
triamcinolone, and dexamethasone but not by deoxycorticos-
terone.
Furthermore, the glucocorticoid e¡ects on mitochondria
seem to vary with age and sex of the rats. With such drugs
we suggest that it is important to discriminate between the
direct e¡ect on mitochondria and the indirect e¡ect involving
nuclear pathway. So we investigated the e¡ects of glucocorti-
coids on isolated mitochondria following a direct incubation.
In order to understand the mechanism, we also studied Ca2
£uxes, swelling and membrane potential.
Our results show that hydrocortisone, prednisolone, triam-
cinolone and dexamethasone decreased the respiratory control
ratio with NAD linked substrates (pyruvate plus malate) or
FADH2 linked substrate (succinate). Interestingly, this de-
crease was concentration-dependent and occurred at low con-
centrations from 10312 to 1037 M. These modi¢cations re-
sulted from a decrease in state 3. The inhibition of oxygen
consumption in decoupled conditions was also observed for
the four drugs. These results suggest that glucocorticoid ef-
fects on oxidative respiration were not predominant on com-
plexes I, II and V. Furthermore the oxygen consumption was
still decreased after the inhibition of complex III indicating
that complex III was not the main target. So, it seems that
glucocorticoids had an inhibitory e¡ect on cytochrome c ox-
idase (complex IV). The intensity of the inhibition was di¡er-
ent between the glucocorticoids studied. When sorted accord-
ing to EC50 value, prednisolone was the most potent inhibitor,
followed by dexamethasone, triamcinolone, and hydrocorti-
sone. When sorted according to complex IV inhibition, the
most potent inhibitor was also prednisolone followed by tri-
amcinolone, dexamethasone and hydrocortisone. Previous
studies have already shown inhibition of complex IV. For
example, L-DOPA inhibited complex IV activity in a human
neuroblastoma cell line (NB69) in a dose-dependent way [15].
It has been suggested that complex IV inhibition by L-DOPA
could contribute to the pathogenesis of Parkinson’s disease
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Table 2
Glucocorticoid e¡ects on mitochondrial membrane potential
Drugs Membrane potential (mV)
Without Ca2 With Ca2 (50 WM)
Control 217.89 þ 7.46 196.75 þ 4.56
Hydrocortisone 215.63 þ 2.97 195.13 þ 4.75
Triamcinolone 216.56 þ 4.92 193.75 þ 7.64
Prednisolone 216.87 þ 6.16 190.42 þ 3.81*
Dexamethasone 215.07 þ 5.79 190.45 þ 4.78*
*P6 0.01. The comparisons were made versus control.
The membrane potential was measured with succinate (10 mM) as
substrate for a mitochondrial protein concentration of 0.5 mg/ml.
Each glucocorticoid concentration was 1 WM. The values are
mean þ S.D. of ¢ve experiments.
Fig. 2. E¡ect of prednisolone on Ca2 £uxes of rat kidney mito-
chondria. At the beginning of the experiment, Ca2 medium concen-
tration was 25 WM. Then mitochondria (2 mg/ml) were added in the
cuvette. The change of Ca2 in medium was recorded with a Ca2-
sensitive electrode system. A downward de£ection corresponded to a
decrease of Ca2 concentration in the medium, i.e. an increase of
mitochondrial Ca2. The medium contained succinate 6 mM and ei-
ther control (dashed line) or prednisolone (solid line) 1 WM. The
data shown are of a representative experiment.
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but this should be con¢rmed. Nitric oxide (NO) inhibited the
complex IV by competing with oxygen [16,17]. The inhibition
was reversible, indicating that NO did not damage the mito-
chondria. The authors suggested that NO could be a physio-
logical regulator of the a⁄nity of the respiratory chain for
oxygen.
We found no e¡ect of glucocorticoids on swelling induced
by Ca2/Pi, and Ca2 £uxes. These results are not in agree-
ment with those of Campbell and Al-Nasser [18]. They ob-
served that dexamethasone inhibited the opening of a Ca2-
dependent, non-speci¢c, pore. However, their observations
were obtained with high concentrations of glucocorticoids
(40^200 WM). In their experiments, the inhibition of the
pore opening started at 40 WM, which could not explain the
e¡ects on respiratory chain we observed at lower concentra-
tions (Table 2).
A direct glucocorticoid regulation on cytochrome c oxidase
activity has been already suggested by Bennett et al. [19]. In-
deed they found that low dose of corticosterone administered
to rats, which did not increase serum corticosterone, acted
synergistically with sodium azide to inhibit cytochrome c ox-
idase activity. Furthermore they showed that chronic cortico-
sterone and sodium azide treatment produced a spatial learn-
ing de¢cit. So they concluded that glucocorticoid treatment
may worsen diseases involving metabolic insults. This is in
agreement with our previous observation that prednisolone
could worsen a mitochondrial toxicity induced by cyclosporin
A [10]. Moreover, glucocorticoids may exacerbate injury in-
duced by hypoxia when cytochrome c oxidase activity is in-
hibited [20]. Many reports have established the damaging
properties of glucocorticoids during ischemic injury. Endoge-
nous corticosterone contributed to the basal level of brain
injury resulting from cerebral ischemia and exocitotoxic seiz-
ure activity, and metapyrone, an inhibitor of glucocorticoid
production, reduced the brain injury induced by focal and
global ischemia and seizure [21]. Glucocorticoids have been
shown to exacerbate both neuronal and astrocytes injury fol-
lowing hypoxia [22]. In a model of myocardial ischemia re-
perfusion, Scheuer and Mi¥in (1997) have shown that the
corticosterone-treated rats had an infarct size signi¢cantly
higher compared to the controls [23]. They concluded that
chronic elevations in plasma corticosterone concentrations
could contribute to the increased risk of cardiovascular dis-
ease in clinical conditions associated with elevated glucocorti-
coid levels.
In general, the steroid molecule is required to penetrate the
cellular membrane and demonstrate a⁄nity for the steroid-
binding site on the glucocorticoid receptor, leading to activa-
tion of the receptor and to the antiin£ammatory activities.
The receptor a⁄nity is a useful parameter that compares the
potency of di¡erent steroids [24]. The EC50 values for the
a⁄nity to the steroid-binding site of hydrocortisone, dexame-
thasone, prednisolone and triamcinolone are 1.30U1038,
1.02U1039, 7.21U1039, and 5.07U10310 M respectively
[25]. Interestingly, the EC50 for the mitochondrial e¡ect is
lower or similar, suggesting a mitochondrial e¡ect in addition
to the nucleus e¡ect at therapeutic concentrations.
In summary, the major ¢ndings of this study are that glu-
cocorticoids inhibit cytochrome c oxidase activity by a direct
mechanism. There are two important issues for these results.
First, glucocorticoids may regulate the cellular metabolism by
a direct action on the respiratory chain. The mechanism sug-
gested is a modulation of cytochrome c oxidative activity.
Second, glucocorticoids may potentiate disease insult in which
oxidative metabolism is altered (ischemia for example).
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